Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Assets and Liabilities at Fair Value (Details)

v3.20.2
Fair Value Measurements - Assets and Liabilities at Fair Value (Details)
1 Months Ended 3 Months Ended
Jan. 31, 2010
contingentValueRightSeries
contingentValueRight
Mar. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Assets:        
Short-term investments     $ 642,373,000 $ 939,989,000
Investment in Viking common stock     43,535,000 48,425,000
Investment in warrants     8,816,000 9,910,000
Total assets     694,724,000 998,324,000
Liabilities:        
Amounts owed to former licensor     107,000 75,000
Total liabilities     11,528,000 9,017,000
Repayments of related party debt   $ 1,800,000    
Number of CVR Series | contingentValueRightSeries 4      
Metabasis        
Liabilities:        
Number of CVRs issued per acquiree share | contingentValueRight 4      
Number of CVRs issued from each CVR series | contingentValueRight 1      
Frequency of cash payments to CVR holders 6 months      
Transferred over Time | Phase 3 Clinical Trial        
Liabilities:        
Contract asset     10,000,000  
Maximum | Transferred over Time | Development, Regulatory, & Commercial Milestones and Tiered Royalties        
Liabilities:        
Investments     375,000,000  
Crystal contingent liabilities        
Liabilities:        
Contingent liabilities     859,000 2,659,000
CyDex contingent liabilities        
Liabilities:        
Contingent liabilities     413,000 348,000
Metabasis contingent liabilities        
Liabilities:        
Contingent liabilities     5,349,000 5,935,000
Icagen contingent liabilities        
Liabilities:        
Contingent liabilities     4,800,000 0
Level 1        
Assets:        
Short-term investments     2,655,000 3,073,000
Investment in Viking common stock     43,535,000 48,425,000
Investment in warrants     8,816,000 9,910,000
Total assets     55,006,000 61,408,000
Liabilities:        
Amounts owed to former licensor     107,000 75,000
Total liabilities     107,000 75,000
Level 1 | Crystal contingent liabilities        
Liabilities:        
Contingent liabilities     0 0
Level 1 | CyDex contingent liabilities        
Liabilities:        
Contingent liabilities     0 0
Level 1 | Metabasis contingent liabilities        
Liabilities:        
Contingent liabilities     0 0
Level 1 | Icagen contingent liabilities        
Liabilities:        
Contingent liabilities     0 0
Level 2        
Assets:        
Short-term investments     639,541,000 936,791,000
Investment in Viking common stock     0 0
Investment in warrants     0 0
Total assets     639,541,000 936,791,000
Liabilities:        
Amounts owed to former licensor     0 0
Total liabilities     5,349,000 5,935,000
Level 2 | Crystal contingent liabilities        
Liabilities:        
Contingent liabilities     0 0
Level 2 | CyDex contingent liabilities        
Liabilities:        
Contingent liabilities     0 0
Level 2 | Metabasis contingent liabilities        
Liabilities:        
Contingent liabilities     5,349,000 5,935,000
Level 2 | Icagen contingent liabilities        
Liabilities:        
Contingent liabilities     0 0
Level 3        
Assets:        
Short-term investments     177,000 125,000
Investment in Viking common stock     0 0
Investment in warrants     0 0
Total assets     177,000 125,000
Liabilities:        
Amounts owed to former licensor     0 0
Total liabilities     6,072,000 3,007,000
Level 3 | Crystal contingent liabilities        
Liabilities:        
Contingent liabilities     859,000 2,659,000
Level 3 | CyDex contingent liabilities        
Liabilities:        
Contingent liabilities     413,000 348,000
Level 3 | Metabasis contingent liabilities        
Liabilities:        
Contingent liabilities     0 0
Level 3 | Icagen contingent liabilities        
Liabilities:        
Contingent liabilities     $ 4,800,000 $ 0